Determinants of infarct size after thrombolytic treatment in acute myocardial infarction

Charles J Bruce, Timothy F. Christian, Gary L. Schaer, Leo J. Spaccavento, Michael K. Jolly, Michael K. O'Connor, Raymond J Gibbons

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Both experimental and single-center clinical studies have shown that myocardium at risk, residual collateral flow, and duration of coronary occlusion are important determinants of final infarct size. The purpose of this study was to replicate these results on a multicenter basis to demonstrate that perfusion imaging using different camera and computer systems can provide reliable assessments of myocardium at risk and collateral flow. Sequential tomographic myocardial perfusion imaging with technetium-99 (Tc-99m) sestamibi was performed in 74 patients with first time myocardial infarction, who were enrolled in a multicenter, randomized, double-blind, placebo-controlled pilot study of poloxamer 188 as ancillary therapy to thrombolysis. All patients underwent thrombolysis within 6 hours of the onset of chest pain. Tc-99m sestamibi was injected intravenously at the initiation of thrombolytic therapy, and tomographic imaging was performed 1 to 6 hours later to assess myocardium at risk. Collateral flow was estimated noninvasively from the acute sestamibi images by 3 methods that assess the severity of the perfusion defect. Final infarct size was determined at hospital discharge by a second sestamibi study. Myocardium at risk (r = 0.61, p <0.0001) and radionuclide estimates of collateral flow (r = 0.58 to 0.66, all p <0.0001) were significantly associated with final infarct size. These associations were independent of the treatment center. On a multivariate basis, myocardium at risk (p = 0.003), the radionuclide estimate of collateral flow (p = 0.03), and treatment arm (p = 0.04) were all independent determinants of infarct size. Time to thrombolytic therapy showed only a trend (p = 0.10). The treatment center was not significant (p = 0.42). Myocardium at risk and collateral flow are important determinants of infarct size that are independent of treatment center. Tomographic imaging with Tc- 99m sestamibi can provide noninvasive assessments of these parameters in multicenter trials of thrombolytic therapy.

Original languageEnglish (US)
Pages (from-to)1600-1605
Number of pages6
JournalAmerican Journal of Cardiology
Volume83
Issue number12
DOIs
StatePublished - Jun 15 1999

Fingerprint

Myocardium
Myocardial Infarction
Thrombolytic Therapy
Radioisotopes
Therapeutics
Technetium Tc 99m Sestamibi
Poloxamer
Myocardial Perfusion Imaging
Perfusion Imaging
Coronary Occlusion
Computer Systems
Chest Pain
Multicenter Studies
Perfusion
Placebos

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Determinants of infarct size after thrombolytic treatment in acute myocardial infarction. / Bruce, Charles J; Christian, Timothy F.; Schaer, Gary L.; Spaccavento, Leo J.; Jolly, Michael K.; O&apos;Connor, Michael K.; Gibbons, Raymond J.

In: American Journal of Cardiology, Vol. 83, No. 12, 15.06.1999, p. 1600-1605.

Research output: Contribution to journalArticle

Bruce, Charles J ; Christian, Timothy F. ; Schaer, Gary L. ; Spaccavento, Leo J. ; Jolly, Michael K. ; O&apos;Connor, Michael K. ; Gibbons, Raymond J. / Determinants of infarct size after thrombolytic treatment in acute myocardial infarction. In: American Journal of Cardiology. 1999 ; Vol. 83, No. 12. pp. 1600-1605.
@article{e064589d251049b5aa0501f80a2ed8c8,
title = "Determinants of infarct size after thrombolytic treatment in acute myocardial infarction",
abstract = "Both experimental and single-center clinical studies have shown that myocardium at risk, residual collateral flow, and duration of coronary occlusion are important determinants of final infarct size. The purpose of this study was to replicate these results on a multicenter basis to demonstrate that perfusion imaging using different camera and computer systems can provide reliable assessments of myocardium at risk and collateral flow. Sequential tomographic myocardial perfusion imaging with technetium-99 (Tc-99m) sestamibi was performed in 74 patients with first time myocardial infarction, who were enrolled in a multicenter, randomized, double-blind, placebo-controlled pilot study of poloxamer 188 as ancillary therapy to thrombolysis. All patients underwent thrombolysis within 6 hours of the onset of chest pain. Tc-99m sestamibi was injected intravenously at the initiation of thrombolytic therapy, and tomographic imaging was performed 1 to 6 hours later to assess myocardium at risk. Collateral flow was estimated noninvasively from the acute sestamibi images by 3 methods that assess the severity of the perfusion defect. Final infarct size was determined at hospital discharge by a second sestamibi study. Myocardium at risk (r = 0.61, p <0.0001) and radionuclide estimates of collateral flow (r = 0.58 to 0.66, all p <0.0001) were significantly associated with final infarct size. These associations were independent of the treatment center. On a multivariate basis, myocardium at risk (p = 0.003), the radionuclide estimate of collateral flow (p = 0.03), and treatment arm (p = 0.04) were all independent determinants of infarct size. Time to thrombolytic therapy showed only a trend (p = 0.10). The treatment center was not significant (p = 0.42). Myocardium at risk and collateral flow are important determinants of infarct size that are independent of treatment center. Tomographic imaging with Tc- 99m sestamibi can provide noninvasive assessments of these parameters in multicenter trials of thrombolytic therapy.",
author = "Bruce, {Charles J} and Christian, {Timothy F.} and Schaer, {Gary L.} and Spaccavento, {Leo J.} and Jolly, {Michael K.} and O&apos;Connor, {Michael K.} and Gibbons, {Raymond J}",
year = "1999",
month = "6",
day = "15",
doi = "10.1016/S0002-9149(99)00164-2",
language = "English (US)",
volume = "83",
pages = "1600--1605",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Determinants of infarct size after thrombolytic treatment in acute myocardial infarction

AU - Bruce, Charles J

AU - Christian, Timothy F.

AU - Schaer, Gary L.

AU - Spaccavento, Leo J.

AU - Jolly, Michael K.

AU - O&apos;Connor, Michael K.

AU - Gibbons, Raymond J

PY - 1999/6/15

Y1 - 1999/6/15

N2 - Both experimental and single-center clinical studies have shown that myocardium at risk, residual collateral flow, and duration of coronary occlusion are important determinants of final infarct size. The purpose of this study was to replicate these results on a multicenter basis to demonstrate that perfusion imaging using different camera and computer systems can provide reliable assessments of myocardium at risk and collateral flow. Sequential tomographic myocardial perfusion imaging with technetium-99 (Tc-99m) sestamibi was performed in 74 patients with first time myocardial infarction, who were enrolled in a multicenter, randomized, double-blind, placebo-controlled pilot study of poloxamer 188 as ancillary therapy to thrombolysis. All patients underwent thrombolysis within 6 hours of the onset of chest pain. Tc-99m sestamibi was injected intravenously at the initiation of thrombolytic therapy, and tomographic imaging was performed 1 to 6 hours later to assess myocardium at risk. Collateral flow was estimated noninvasively from the acute sestamibi images by 3 methods that assess the severity of the perfusion defect. Final infarct size was determined at hospital discharge by a second sestamibi study. Myocardium at risk (r = 0.61, p <0.0001) and radionuclide estimates of collateral flow (r = 0.58 to 0.66, all p <0.0001) were significantly associated with final infarct size. These associations were independent of the treatment center. On a multivariate basis, myocardium at risk (p = 0.003), the radionuclide estimate of collateral flow (p = 0.03), and treatment arm (p = 0.04) were all independent determinants of infarct size. Time to thrombolytic therapy showed only a trend (p = 0.10). The treatment center was not significant (p = 0.42). Myocardium at risk and collateral flow are important determinants of infarct size that are independent of treatment center. Tomographic imaging with Tc- 99m sestamibi can provide noninvasive assessments of these parameters in multicenter trials of thrombolytic therapy.

AB - Both experimental and single-center clinical studies have shown that myocardium at risk, residual collateral flow, and duration of coronary occlusion are important determinants of final infarct size. The purpose of this study was to replicate these results on a multicenter basis to demonstrate that perfusion imaging using different camera and computer systems can provide reliable assessments of myocardium at risk and collateral flow. Sequential tomographic myocardial perfusion imaging with technetium-99 (Tc-99m) sestamibi was performed in 74 patients with first time myocardial infarction, who were enrolled in a multicenter, randomized, double-blind, placebo-controlled pilot study of poloxamer 188 as ancillary therapy to thrombolysis. All patients underwent thrombolysis within 6 hours of the onset of chest pain. Tc-99m sestamibi was injected intravenously at the initiation of thrombolytic therapy, and tomographic imaging was performed 1 to 6 hours later to assess myocardium at risk. Collateral flow was estimated noninvasively from the acute sestamibi images by 3 methods that assess the severity of the perfusion defect. Final infarct size was determined at hospital discharge by a second sestamibi study. Myocardium at risk (r = 0.61, p <0.0001) and radionuclide estimates of collateral flow (r = 0.58 to 0.66, all p <0.0001) were significantly associated with final infarct size. These associations were independent of the treatment center. On a multivariate basis, myocardium at risk (p = 0.003), the radionuclide estimate of collateral flow (p = 0.03), and treatment arm (p = 0.04) were all independent determinants of infarct size. Time to thrombolytic therapy showed only a trend (p = 0.10). The treatment center was not significant (p = 0.42). Myocardium at risk and collateral flow are important determinants of infarct size that are independent of treatment center. Tomographic imaging with Tc- 99m sestamibi can provide noninvasive assessments of these parameters in multicenter trials of thrombolytic therapy.

UR - http://www.scopus.com/inward/record.url?scp=0033564282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033564282&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(99)00164-2

DO - 10.1016/S0002-9149(99)00164-2

M3 - Article

C2 - 10392861

AN - SCOPUS:0033564282

VL - 83

SP - 1600

EP - 1605

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 12

ER -